Every 10-Q that SkinHealth Systems Inc. (SKIN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SKIN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKIN filings page.
The Beauty Health Company (SKIN) filed its Q3 2025 10‑Q, reporting net sales of $70.655 million, down 10.3% year over year. Gross profit was $45.634 million, lifting gross margin to 64.6% from 51.6% a year ago as cost of sales fell. The company posted a loss from operations of $6.242 million and a net loss of $11.031 million, both improved versus last year.
Delivery Systems revenue declined 24.6% to $20.819 million, while Consumables slipped 2.6% to $49.836 million. Operating cash flow was $22.289 million for the nine months. Cash, cash equivalents, and restricted cash were $219.397 million, and inventories were $56.146 million.
Capital structure shifted with privately negotiated exchanges and repurchases of the 1.25% 2026 notes. The company issued $250.0 million of 7.95% Convertible Senior Secured Notes due 2028 (initial conversion rate 349.6503 shares per $1,000, or ~$2.86 per share) and recognized related net gains. Convertible senior notes, net, totaled $363.388 million at quarter end. As of November 3, 2025, Class A shares outstanding were 127,503,059.